GlobeNewswire·Nov 9, 2026, 4:01 PM ET

Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results

SEPN

Phase 1 clinical trial for oral PTH1R agonist SEP-479 is ongoing, with single-ascending dose & multiple-ascending dose data expected in Q1 2027.
Plans are in place to initiate a Phase 1 clinical trial for the oral TSHR NAM development candidate SEP-204 in Q1 2027.
SEP-204 was selected as a development candidate for Graves' disease & thyroid eye disease based on preclinical data showing potent TSHR inhibition & favorable safety profiles.
SEP-631, an oral MRGPRX2 NAM for mast cell-driven diseases, continues evaluation following positive Phase 1 results reported in March 2026.
Global collaboration with Novo Nordisk, initiated in July 2025, has yielded $13 million in research milestones & includes a development candidate for which Novo assumed IND-enabling toxicology responsibility.
Rajiv Patni, M.D., was appointed Chief Medical Officer in August 2026.
Cash, cash equivalents, & marketable securities totaled $565.2 million as of September 30, 2026, supporting operations through at least mid-2029.
Revenue for the third quarter ended September 30, 2026, was $18.9 million, down from $21.5 million in the prior year quarter.
Research & development expenses were $36.6 million for the quarter, compared to $24.3 million in the same period last year.
General & administrative expenses were $9.6 million for the quarter, compared to $7.1 million in the same period last year.
Net loss for the quarter ended September 30, 2026, was $26.6 million, contrasting with a net income of $8.2 million in the same period last year.

Company: Septerna, Inc.
Keywords: Nasdaq:SEPN, Septerna, Inc.